- Home
- CGEN vs PDEX Comparison
CGEN vs PDEX Comparison
Compare CGEN & PDEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- PDEX
- Stock Information
- Founded
- CGEN 1993
- PDEX 1978
- Country
- CGEN Israel
- PDEX United States
- Employees
- CGEN N/A
- PDEX N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- PDEX Medical/Dental Instruments
- Sector
- CGEN Health Care
- PDEX Health Care
- Exchange
- CGEN Nasdaq
- PDEX Nasdaq
- Market Cap
- CGEN 167.4M
- PDEX 167.6M
- IPO Year
- CGEN 2000
- PDEX N/A
- Fundamental
- Price
- CGEN $1.64
- PDEX $40.90
- Analyst Decision
- CGEN
- PDEX Strong Buy
- Analyst Count
- CGEN 0
- PDEX 1
- Target Price
- CGEN N/A
- PDEX $56.00
- AVG Volume (30 Days)
- CGEN 264.8K
- PDEX 35.7K
- Earning Date
- CGEN 08-05-2025
- PDEX 05-01-2025
- Dividend Yield
- CGEN N/A
- PDEX N/A
- EPS Growth
- CGEN N/A
- PDEX 379.10
- EPS
- CGEN N/A
- PDEX 2.76
- Revenue
- CGEN $27,589,000.00
- PDEX $64,123,999.00
- Revenue This Year
- CGEN N/A
- PDEX $26.92
- Revenue Next Year
- CGEN $173.80
- PDEX $4.48
- P/E Ratio
- CGEN N/A
- PDEX $14.68
- Revenue Growth
- CGEN N/A
- PDEX 29.65
- 52 Week Low
- CGEN $1.13
- PDEX $16.84
- 52 Week High
- CGEN $2.66
- PDEX $70.26
- Technical
- Relative Strength Index (RSI)
- CGEN 54.29
- PDEX 44.83
- Support Level
- CGEN $1.65
- PDEX $39.92
- Resistance Level
- CGEN $1.83
- PDEX $43.12
- Average True Range (ATR)
- CGEN 0.10
- PDEX 2.11
- MACD
- CGEN -0.01
- PDEX 0.40
- Stochastic Oscillator
- CGEN 47.50
- PDEX 57.39
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About PDEX Pro-Dex Inc.
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.